Search Results - "Halliday, Glenda M."

Refine Results
  1. 1

    Glia: Initiators and progressors of pathology in Parkinson's disease by Halliday, Glenda M., Stevens, Claire H.

    Published in Movement disorders (01-01-2011)
    “…Background: Glia are traditionally known as support cells for neurons, and their role in neurodegeneration has been largely considered secondary to neuronal…”
    Get full text
    Journal Article
  2. 2

    Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology by Dzamko, Nicolas, Gysbers, Amanda, Perera, Gayathri, Bahar, Anita, Shankar, Amrita, Gao, Jianqun, Fu, YuHong, Halliday, Glenda M.

    Published in Acta neuropathologica (01-02-2017)
    “…Inflammation is likely a key contributor to the pathogenesis of Parkinson’s disease (PD), a progressively debilitating neurodegenerative disease that is…”
    Get full text
    Journal Article
  3. 3

    The frontotemporal dementia-motor neuron disease continuum by Burrell, James R, PhD, Halliday, Glenda M, Prof, Kril, Jillian J, Prof, Ittner, Lars M, Prof, Götz, Jürgen, Prof, Kiernan, Matthew C, Prof, Hodges, John R, Prof

    Published in The Lancet (British edition) (27-08-2016)
    “…Summary Early reports of cognitive and behavioural deficits in motor neuron disease might have been overlooked initially, but the concept of a frontotemporal…”
    Get full text
    Journal Article
  4. 4

    Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts by Strohäker, Timo, Jung, Byung Chul, Liou, Shu-Hao, Fernandez, Claudio O., Riedel, Dietmar, Becker, Stefan, Halliday, Glenda M., Bennati, Marina, Kim, Woojin S., Lee, Seung-Jae, Zweckstetter, Markus

    Published in Nature communications (04-12-2019)
    “…Parkinson’s disease (PD) and Multiple System Atrophy (MSA) are clinically distinctive diseases that feature a common neuropathological hallmark of aggregated…”
    Get full text
    Journal Article
  5. 5

    Disease duration and the integrity of the nigrostriatal system in Parkinson's disease by KORDOWER, Jeffrey H, WARREN OLANOW, C, DODIYA, Hemraj B, YAPING CHU, BEACH, Thomas G, ADLER, Charles H, HALLIDAY, Glenda M, BARTUS, Raymond T

    Published in Brain (London, England : 1878) (01-08-2013)
    “…The pace of nigrostriatal degeneration, both with regards to striatal denervation and loss of melanin and tyrosine hydroxylase-positive neurons, is poorly…”
    Get full text
    Journal Article
  6. 6

    Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders by Werry, Eryn L, Bright, Fiona M, Piguet, Olivier, Ittner, Lars M, Halliday, Glenda M, Hodges, John R, Kiernan, Matthew C, Loy, Clement T, Kril, Jillian J, Kassiou, Michael

    “…Neuroinflammation is an inflammatory response in the brain and spinal cord, which can involve the activation of microglia and astrocytes. It is a common…”
    Get full text
    Journal Article
  7. 7

    Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework by Matar, Elie, Shine, James M, Halliday, Glenda M, Lewis, Simon J G

    Published in Brain (London, England : 1878) (01-01-2020)
    “…Fluctuating cognition is a complex and disabling symptom that is seen most frequently in the context of Lewy body dementias encompassing dementia with Lewy…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    The neurobiological basis of cognitive impairment in Parkinson's disease by Halliday, Glenda M., Leverenz, James B., Schneider, Jay S., Adler, Charles H.

    Published in Movement disorders (15-04-2014)
    “…ABSTRACT The recent formalization of clinical criteria for Parkinson's disease with dementia (PDD) codifies many studies on this topic, including those…”
    Get full text
    Journal Article
  11. 11

    Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria by Dickson, Dennis W, MD, Braak, Heiko, MD, Duda, John E, MD, Duyckaerts, Charles, MD, Gasser, Thomas, MD, Halliday, Glenda M, PhD, Hardy, John, PhD, Leverenz, James B, MD, Del Tredici, Kelly, MD, Wszolek, Zbigniew K, MD, Litvan, Irene, MD

    Published in Lancet neurology (01-12-2009)
    “…Summary To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis by Gabery, Sanaz, Ahmed, Rebekah M, Caga, Jashelle, Kiernan, Matthew C, Halliday, Glenda M, Petersén, Åsa

    Published in Neuropathology and applied neurobiology (01-12-2021)
    “…Aims To determine the underlying cellular changes and clinical correlates associated with pathology of the hypothalamus in amyotrophic lateral sclerosis (ALS),…”
    Get full text
    Journal Article
  14. 14

    Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease by Murphy, Karen E., Gysbers, Amanda M., Abbott, Sarah K., Spiro, Adena S., Furuta, Akiko, Cooper, Antony, Garner, Brett, Kabuta, Tomohiro, Halliday, Glenda M.

    Published in Movement disorders (01-10-2015)
    “…ABSTRACT Lysosomes are the primary catabolic compartment for the degradation of intracellular proteins through autophagy. The presence of abnormal…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism by Ahmed, Rebekah M, Dr, Irish, Muireann, PhD, Piguet, Olivier, PhD, Halliday, Glenda M, Prof, Ittner, Lars M, Prof, Farooqi, Sadaf, Prof, Hodges, John R, Prof, Kiernan, Matthew C, Prof

    Published in Lancet neurology (01-03-2016)
    “…Summary Metabolic changes incorporating fluctuations in weight, insulin resistance, and cholesterol concentrations have been identified in several…”
    Get full text
    Journal Article
  17. 17

    LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients by Atashrazm, Farzaneh, Hammond, Deborah, Perera, Gayathri, Bolliger, Marc F., Matar, Elie, Halliday, Glenda M., Schüle, Birgitt, Lewis, Simon J.G., Nichols, R. Jeremy, Dzamko, Nicolas

    Published in Movement disorders (01-03-2019)
    “…Background Leucine‐rich repeat kinase 2 is a potential therapeutic target for the treatment of Parkinson's disease, and clinical trials of leucine‐rich repeat…”
    Get full text
    Journal Article
  18. 18

    The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years by Hely, Mariese A., Reid, Wayne G.J., Adena, Michael A., Halliday, Glenda M., Morris, John G.L.

    Published in Movement disorders (30-04-2008)
    “…After 20 years follow‐up of newly diagnosed patients with Parkinson's disease (PD), 100 of 136 (74%) have died. The mortality rate fell in the first 3 years of…”
    Get full text
    Journal Article
  19. 19

    Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease by Coupland, Kirsten G, Kim, Woojin S, Halliday, Glenda M, Hallupp, Marianne, Dobson-Stone, Carol, Kwok, John B J

    Published in PloS one (23-06-2016)
    “…Studies investigating the pathogenic role of the microtubule associated protein tau (MAPT) gene in Parkinson's disease (PD) have indicated that DNA methylation…”
    Get full text
    Journal Article
  20. 20

    Neuronal network disintegration: common pathways linking neurodegenerative diseases by Ahmed, Rebekah M, Devenney, Emma M, Irish, Muireann, Ittner, Arne, Naismith, Sharon, Ittner, Lars M, Rohrer, Jonathan D, Halliday, Glenda M, Eisen, Andrew, Hodges, John R, Kiernan, Matthew C

    “…Neurodegeneration refers to a heterogeneous group of brain disorders that progressively evolve. It has been increasingly appreciated that many…”
    Get full text
    Journal Article Book Review